

Post-neoadjuvant assessment of tumour budding according to ITBCC subgroups delivers stage- and regression-grade independent prognostic information in intestinal-type gastric adenocarcinoma

M Jesinghaus *et al. J Pathol Clin Res* DOI: 10.1002/cjp2.284

Supplementary Tables S1 – S3

Table S1. Detailed listing of the applied chemotherapy regimens.

Fluoropyrimidine + Cisplatin	60 (36%)
Fluoropyrimidine + Oxaliplatin	28 (17%)
Fluoropyrimidine + Oxaliplatin + Docetaxel	15 (9%)
Fluoropyrimidine + Cisplatin + Paclitaxel	10 (6%)
Fluoropyrimidine + Oxaliplatin + Epirubicin	43 (26%)
Platin + Imatinib/Panitumumab/Cetuximab...	6 (3%)
Others	5 (3%)
Adjuvant therapy after the resection	25 (15%)

Table S2. Detailed survival of the ITBCC tumour budding subgroups within the overall cohort and in specific subgroups (mean and median survival)

		Overall n (%)	Mean overall survival (95% confidence interval)	Median overall survival (95 % confidence interval)	<i>p-value (log-rank)</i>
Whole cohort	Bd1	49 (29.3%)	51.7 (46.5-56.8)	not reached	< 0.001
	Bd2	41 (24.5%)	37.4 (30.3-44.5)	35.1 (16.2-53.9)	
	Bd3	77 (46.1%)	28.1 (23.2-33.1)	23.6 (15.3-31.9)	
UICC stage 1/2	Bd1	36 (44.4%)	54.7 (50.1-59.3)	not reached	0.002
	Bd2	16 (19.7%)	42.1 (31.3-52.9)	not reached	
	Bd3	29 (35.8%)	38.4 (30.2-46.6)	35.9 (18.8-52.9)	
UICC stage 3/4	Bd1	13 (22.1%)	42.8 (29.1-56.6)	not reached	0.003
	Bd2	25 (26.5%)	34.1 (25.0-43.2)	25.5 (22.3-28.6)	
	Bd3	48 (51.4%)	21.8 (16.4-27.1)	16.8 (15.6-17.9)	
TRG 1	Bd1	11 (58%)	47.0 (34.5-59.5)	not reached	***
	Bd2	3 (15.8%)	40.2 (20.3-59.9)	43.1 (1.9-60.0)	
	Bd3	5 (26.2%)	39.8 (24.2-55.2)	35.9 (16.7-55.0)	
TRG 2	Bd1	16 (23.9%)	55.2 (48.1-60.0)	not reached	< 0.001
	Bd2	21 (31.3%)	34.6 (24.9-44.2)	27.2 (22.8-31.5)	
	Bd3	30 (44.7%)	27.9 (20.7-35.1)	16.8 (14.6-18.9)	
TRG 3	Bd1	22 (27.2%)	51.5 (43.6-59.3)	not reached	< 0.001
	Bd2	17 (21%)	41.1 (29.4-52.7)	not reached	
	Bd3	42 (51.8%)	26.6 (19.5-33.7)	17.1 (5.3-28.8)	
MSS	Bd1	36(25.2%)	50.2 (43.9-56.5)	not reached	< 0.001
	Bd2	36 (25.2%)	38.8 (31.1-46.6)	not reached	
	Bd3	71 (49.6%)	26.7 (21.6-31.6)	18.1 (9.4-26.7)	
MSI-H	Bd1	6 (50%)	all cases censored	not reached	***
	Bd2	2 (16.7%)	14.7 (2.3-27.1)	not reached	
	Bd3	4 (33.3%)	42.4 (20.7-64.1)	not reached	

R0 resected cases	Bd1	46 (34.8%)	52.2 (47.1-57.3)	not reached	<0.001
	Bd2	33 (25%)	39.9 (31.7-48.1)	not reached	
	Bd3	53 (40.2%)	30.2 (24.2-36.2)	27.0 (14.2-39.7)	
R1 resected cases	Bd1	3 (8.7%)	43.9 (18.1-69.3)	not reached	***
	Bd2	8 (22.8%)	26.5 (17.0-36.0)	25.3 (15.8-34.7)	
	Bd3	24 (68.5%)	22.5 (14.4-30.6)	16.8 (15.2-18.3)	

*** p values not given because too few events were present for a log-rank test in these subgroups.

Table S3. Detailed interobserver analysis regarding the ITBCC tumour budding subgroups between two observers

		Observer 2			Number of cases	Kappa-value	p-value
		Bd1	Bd2	Bd3			
Observer 1	Bd1	6	2	0	8		
	Bd2	0	4	0	4		
	Bd3	0	2	16	18		
Number of cases		6	8	16	30	0.77	<0.001